文献速递血栓与止血

血友病临床基因治疗进展

Update on clinical gene therapy for hemophilia.
PubMed 文献 · Blood · 2018-12-17

本综述总结了血友病基因治疗的临床进展。通过肝脏体内基因转移,使用不同衣壳的腺相关病毒载体表达凝血因子,已在患者中实现接近完全纠正血友病A和B。患者数据支持持续内源性凝血因子产生可消除输注需求并可能降低治疗费用,但部分接受高载体剂量者出现轻度肝毒性,且部分与针对病毒衣壳的T细胞反应相关而需免疫抑制;预先存在的病毒衣壳免疫也限制部分患者治疗。

要点

  • 肝脏体内基因转移已在患者中实现血友病A和B接近完全纠正。
  • 持续内源性凝血因子产生可消除凝血因子输注需求并可能降低治疗费用。
  • 部分接受高载体剂量者出现轻度肝毒性,部分与抗衣壳T细胞反应相关而需免疫抑制。

核心结论

  • 基因治疗有望通过单次给药实现血友病的持久治愈,已在患者中实现接近完全纠正。

研究设计与样本

  • 综述总结了血友病临床基因治疗的进展与持续开发。

主要发现

  • 使用不同病毒衣壳的腺相关病毒载体表达高水平凝血因子,在部分情况下表达超活性凝血因子。
  • 患者数据支持持续内源性凝血因子产生可消除凝血因子输注需求,并可能最终降低治疗费用。
  • 部分接受高载体剂量者出现轻度肝毒性,部分与针对病毒衣壳的T细胞反应相关而需免疫抑制。
  • 因预先存在的病毒衣壳免疫,并非所有患者均可治疗。
  • 动物模型研究提示该方法也可用于免疫耐受诱导,以预防或消除针对凝血因子的抑制性抗体。

局限性

  • 部分接受高载体剂量者出现轻度肝毒性。
  • 部分肝毒性事件与针对病毒衣壳的T细胞反应相关,需使用免疫抑制。
  • 因预先存在的病毒衣壳免疫,并非所有患者均可治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In contrast to other diverse therapies for the X-linked bleeding disorder hemophilia that are currently in clinical development, gene therapy holds the promise of a lasting cure with a single drug administration. Near-to-complete correction of hemophilia A (factor VIII deficiency) and hemophilia B (factor IX deficiency) have now been achieved in patients by hepatic in vivo gene transfer. Adeno-associated viral vectors with different viral capsids that have been engineered to express high-level, and in some cases hyperactive, coagulation factors were employed. Patient data support that sustained endogenous production of clotting factor as a result of gene therapy eliminates the need for infusion of coagulation factors (or alternative drugs that promote coagulation), and may therefore ultimately also reduce treatment costs. However, mild liver toxicities have been observed in some patients receiving high vector doses. In some but not all instances, the toxicities correlated with a T-cell response directed against the viral capsid, prompting use of immune suppression. In addition, not all patients can be treated because of preexisting immunity to viral capsids. Nonetheless, studies in animal models of hemophilia suggest that the approach can also be used for immune tolerance induction to prevent or eliminate inhibitory antibodies against coagulation factors. These can form in traditional protein replacement therapy and represent a major complication of treatment. The current review provides a summary and update on advances in clinical gene therapies for hemophilia and its continued development.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Perrin GQ, Herzog RW, Markusic DM, et al. Update on clinical gene therapy for hemophilia. Blood. 2018. PMID: 30559260. doi:10.1182/blood-2018-07-820720

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。